-

12:02:36 PM

LIAN Stock News

LIAN - LianBio

08/28/23 4:05 PM

Nasdaq : LIAN

clinical trial

LianBio Announces Results from Phase 3 EXPLORER-CN Trial of Mavacamten Presented at the European Society of Cardiology Congress and Simultaneous Publication in JAMA Cardiology

EXPLORER-CN data presented in oral late-breaking science session at ESC 2023 Data from the trial published simultaneously in JAMA Cardiology Mavacamten demonstrated improvement in Valsalva LVOT peak gradient, LVOT obstruction, clinical symptoms, health status, cardiac biomarkers, and cardiac

RHEA-AI

neutral

08/14/23 4:05 PM

Nasdaq : LIAN

earnings

LianBio Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Mavacamten New Drug Application (NDA) under priority review with China National Medical Products Administration ( NMPA) Phase 3 EXPLORER-CN trial of mavacamten in Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) met primary endpoint Data from EXPLORER-CN trial to be

RHEA-AI

positive

08/03/23 4:05 PM

Nasdaq : LIAN

clinical trial

LianBio Announces First Patient Treated in Phase 1 Trial of SHP2 Inhibitor BBP-398 in Combination with Osimertinib in Patients with Non-Small Cell Lung Cancer with EGFR Mutations

LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced the first patient has been dosed in its Phase 1 clinical trial of

RHEA-AI

positive

07/26/23 8:30 AM

Nasdaq : LIAN

fda approval

LianBio Partner Tarsus Pharmaceuticals Announces U.S. FDA Approval of XDEMVY™ (lotilaner ophthalmic solution) 0.25% for the Treatment of Demodex Blepharitis

LianBio’s (Nasdaq: LIAN) partner, Tarsus Pharmaceuticals (Tarsus), announced yesterday that the U.S. Food and Drug Administration (FDA) approved XDEMVY™ (lotlilaner ophthalmic solution) 0.25% for the treatment of Demodex

RHEA-AI

neutral

07/18/23 8:00 AM

Nasdaq : LIAN

LianBio Partner NANOBIOTIX Enters into License Agreement with Janssen for Radioenhancer NBTXR3, with LianBio Retaining Development and Commercialization Rights in Greater China, South Korea, Singapore and Thailand

LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced that partner Nanobiotix has entered into a license agreement with

RHEA-AI

positive

07/17/23 6:00 AM

Nasdaq : LIAN

clinical trial

LianBio Announces Phase 3 EXPLORER-CN Data Accepted for Late-Breaking Presentation at the European Society of Cardiology Congress 2023

LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced data from the Phase 3 EXPLORER-CN trial of mavacamten in Chinese

RHEA-AI

neutral

07/12/23 8:00 AM

Nasdaq : LIAN

LianBio Announces Clinical Supply Agreement with AstraZeneca in China to Evaluate BBP-398 in Combination with Osimertinib in Patients with Non-Small Cell Lung Cancer with EGFR Mutations

LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced a clinical supply agreement with AstraZeneca in China to evaluate

RHEA-AI

positive

06/26/23 8:00 AM

Nasdaq : LIAN

LianBio Announces Marketing Approval of CAMZYOS® (mavacamten) in Singapore

LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other Asian markets, today announced that CAMZYOS ® (mavacamten) has received marketing approval for the

RHEA-AI

neutral

06/08/23 7:00 AM

Nasdaq : LIAN

clinical trial

LianBio Completes Enrollment in Pivotal Phase 3 LIBRA Trial of TP-03 in Chinese Patients with Demodex Blepharitis

LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients

RHEA-AI

neutral

06/06/23 4:05 PM

Nasdaq : LIAN

clinical trial

LianBio Announces Topline Results from Phase 2a Proof of Concept Trial Evaluating Infigratinib in Patients with Gastric Cancer & Receipt of Breakthrough Therapy Designation in China

LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced positive topline results from a Phase 2a proof of concept trial

RHEA-AI

positive

1 2 3 4 5 6 Next